Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Vaccines in the era of genomics: the pneumococcal challenge.

Barocchi MA, Censini S, Rappuoli R.

Vaccine. 2007 Apr 20;25(16):2963-73. Epub 2007 Jan 30. Review.

PMID:
17324490
2.

Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.

Meng C, Lin H, Huang J, Wang H, Cai Q, Fang L, Guo Y.

Microb Pathog. 2009 Sep;47(3):151-6. doi: 10.1016/j.micpath.2009.05.004. Epub 2009 May 23.

PMID:
19467319
4.

Developing antibacterial vaccines in genomics and proteomics era.

Kaushik DK, Sehgal D.

Scand J Immunol. 2008 Jun;67(6):544-52. doi: 10.1111/j.1365-3083.2008.02107.x. Epub 2008 Apr 4. Review.

5.

Confronting the pneumococcus: a target shift or bullet change?

Obaro SK.

Vaccine. 2000 Dec 8;19(9-10):1211-7. Review.

PMID:
11137259
6.

Genome-based approaches to develop vaccines against bacterial pathogens.

Serruto D, Serino L, Masignani V, Pizza M.

Vaccine. 2009 May 26;27(25-26):3245-50. doi: 10.1016/j.vaccine.2009.01.072. Epub 2009 Feb 5. Review.

PMID:
19200820
7.
8.

Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era.

Dinleyici EC, Yargic ZA.

Expert Rev Vaccines. 2008 Nov;7(9):1367-94. doi: 10.1586/14760584.7.9.1367. Review.

PMID:
18980540
9.

Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species.

Pletz MW, Maus U, Krug N, Welte T, Lode H.

Int J Antimicrob Agents. 2008 Sep;32(3):199-206. doi: 10.1016/j.ijantimicag.2008.01.021. Epub 2008 Apr 18. Review.

PMID:
18378430
10.

Pneumococcal conjugate vaccines. A review.

Galiza EP, Heath PT.

Minerva Med. 2007 Apr;98(2):131-43. Review.

PMID:
17519855
11.

Understanding the link between pneumococcal serotypes and invasive disease.

Soley C, Arguedas A.

Vaccine. 2009 Aug 21;27 Suppl 3:C19-21. doi: 10.1016/j.vaccine.2009.06.003. Epub 2009 Jun 16.

PMID:
19535183
12.

Identification of potential vaccine candidates against Streptococcus pneumoniae by reverse vaccinology approach.

Talukdar S, Zutshi S, Prashanth KS, Saikia KK, Kumar P.

Appl Biochem Biotechnol. 2014 Mar;172(6):3026-41. doi: 10.1007/s12010-014-0749-x. Epub 2014 Jan 31.

PMID:
24482282
13.

Peptide mimics of two pneumococcal capsular polysaccharide serotypes (6B and 9V) protect mice from a lethal challenge with Streptococcus pneumoniae.

Smith CM, Lo Passo C, Scuderi A, Kolberg J, Baxendale H, Goldblatt D, Oggioni MR, Felici F, Andrew PW.

Eur J Immunol. 2009 Jun;39(6):1527-35. doi: 10.1002/eji.200839091.

14.

Identification of proteins in Streptococcus pneumoniae by reverse vaccinology and genetic diversity of these proteins in clinical isolates.

Argondizzo AP, da Mota FF, Pestana CP, Reis JN, de Miranda AB, Galler R, Medeiros MA.

Appl Biochem Biotechnol. 2015 Feb;175(4):2124-65. doi: 10.1007/s12010-014-1375-3. Epub 2014 Dec 2.

PMID:
25448632
15.

The use of genomics in microbial vaccine development.

Bambini S, Rappuoli R.

Drug Discov Today. 2009 Mar;14(5-6):252-60. doi: 10.1016/j.drudis.2008.12.007. Epub 2009 Jan 15. Review.

PMID:
19150507
16.

Combat pneumococcal infections: adhesins as candidates for protein-based vaccine development.

Gamez G, Hammerschmidt S.

Curr Drug Targets. 2012 Mar;13(3):323-37. Review.

PMID:
22206255
17.

Mucosal immunization with polyamine transport protein D (PotD) protects mice against nasopharyngeal colonization with Streptococcus pneumoniae.

Shah P, Briles DE, King J, Hale Y, Swiatlo E.

Exp Biol Med (Maywood). 2009 Apr;234(4):403-9. doi: 10.3181/0809-RM-269. Epub 2009 Jan 28.

PMID:
19176871
18.

Distinct approaches to investigate the importance of the murine 4-1BB 4-1BBL interaction in the antibody response to Streptococcus pneumoniae.

Moens L, Jeurissen A, Mittler RS, Wuyts G, Michiels G, Boon L, Ceuppens JL, Bossuyt X.

J Leukoc Biol. 2007 Sep;82(3):638-44. Epub 2007 Jun 5.

PMID:
17550973
19.

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.

Wysocki J, Tejedor JC, Grunert D, Konior R, Garcia-Sicilia J, Knuf M, Bernard L, Dieussaert I, Schuerman L.

Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S77-88. doi: 10.1097/INF.0b013e318199f609.

PMID:
19325450
20.

Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada.

Feavers I, Knezevic I, Powell M, Griffiths E; WHO Consultation on Serological Criteria for Evaluation and Licensing of New Pneumococcal Vaccines.

Vaccine. 2009 Jun 8;27(28):3681-8. doi: 10.1016/j.vaccine.2009.03.087. Epub 2009 Apr 17.

PMID:
19442421

Supplemental Content

Support Center